Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Vittorina Zagonel et al.|The Lancet Oncology|2016Cited by 1k
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancerAlessio Amatu, Salvatore Siena|Annals of Oncology|2019Cited by 300
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trialAndrea Sartore‐Bianchi, Alberto Bardelli, Filippo Pietrantonio et al.|Nature Medicine|2022Cited by 259